Skip to main content

Table 4 Time-dependent Cox regression model: Adjusted risk factors for cardiac events at the age of 18–40 years in the 249 LQT1 and LQT2 patients who were treated with β-blocker medicationa

From: Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patients

 

Hazard ratio

95% confidence interval

P-value

BB vs no BB in non-FF

0.40

0.29–0.57

< 0.001

BB vs no BB in KCNQ1 G589D

0.19

0.09–0.41

< 0.001

BB vs no BB in other FF

0.30

0.18–0.51

< 0.001

Non-compliance vs compliance

1.87

1.35–2.59

< 0.001

Side effects vs no side effects

1.08

0.80–1.47

0.61

  1. aPatients with > 1 LQTS-causing mutation (n = 7) are excluded
  2. β-blocker treatment was considered in a time-dependent manner
  3. The effect of β-blocker treatment is shown separately for carriers of non-FF, KCNQ1 G589D, or other FF mutation
  4. The β-blockers used were bisoprolol (43%), propranolol (33%), atenolol (12%), metoprolol (10%), acebutolol (2%), and betaxolol (1%)
  5. The model was adjusted for gender, QTc duration, cardiac events before age 18, and family membership
  6. A separate QTc missing covariate was used for patients whose QTc data were unavailable
  7. BB = β-blocker
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us